Allison Naleway, PhD, is a distinguished investigator whose research focuses on the evaluation of vaccine safety and effectiveness and on the surveillance of vaccine-preventable or other infectious diseases. Dr. Naleway is an investigator with the CDC-funded Vaccine Safety Datalink, a national project that links electronic medical records data from several integrated health care delivery organizations to monitor vaccine safety. Additionally, she has collaborated with the CDC on studies to assess the effectiveness of influenza vaccination during pregnancy, influenza vaccine choice and effectiveness in health care personnel, and the early effects of human papillomavirus vaccination on HPV-related outcomes.
Dr. Naleway received her master’s and doctoral degrees in epidemiology from The University of Iowa’s College of Public Health and completed a postdoctoral fellowship in epidemiology at the Marshfield Clinic Research Foundation. She has an adjunct faculty appointment with The University of Iowa College of Public Health’s Department of Epidemiology. She joined CHR in 2003.
Selected Current Studies
- Vaccine Safety Datalink-Infrastructure Activities (CDC)
- Multi-Country Investigation of Vaccine Effectiveness Against Hospitalized Influenza in Pregnant Women (CDC)
- Prevention of Injection Site Pain and Syncope Associated with Preteen and Teen Vaccination—PAVE (NVPO)
- Epidemiology of Novel Influenza Virus Infection and Evaluation of Antiviral and Vaccine Effectiveness “Flu Pandemic” (CDC)
- Henninger ML, Irving SA, Thompson M, Avalos LA, Ball SW, Shifflett P, Naleway AL for the Pregnancy and Influenza Project (PIP) Working Group. Factors associated with seasonal influenza vaccination in pregnant women. J Womens Health 2015; 24:394-402. Epub 2015 Apr 15.
- Naleway AL, Weinmann S, Krishnarajah S, Arondekar B, Fernandez J, Swamy G, Myers E. Pregnancy after treatment for cervical cancer precursor lesions in a retrospective matched cohort. PLOS One 2015; 10:e0117525.
- Naleway AL, Weinmann S, Crane B, Gee J, Markowitz LE, Dunne EF. Evaluation of a surveillance case definition for anogenital warts, Kaiser Permanente Northwest. Sex Transm Dis 2014; 41:496-500.
- Naleway AL, Irving SA, Henninger ML, Li D, Shifflett P, Ball S, Williams J, Cragan J, Gee J, Thompson MG. Safety of influenza vaccination during pregnancy: a review of subsequent maternal obstetric events and findings from two recent cohort studies. Vaccine 2014; 32:3122-7. Epub 2014 Apr 14.
- Naleway AL, Henkle EM, Ball S, Bozeman S, Gaglani MJ, Kennedy ED, Thompson MG. Barriers and facilitators to influenza vaccination and vaccine coverage in a cohort of healthcare personnel. Am J Infect Control 2014; 42:371-5.
- Naleway AL, Kurosky S, Henninger ML, Gold R, Nordin JD, Kharbanda EO, Irving S, Cheetham TC, Nakasato C, Glanz J, Hambidge SJ, Davis RL, Klein NP, McCarthy NL, Weintraub S. Vaccinations given during pregnancy, 2002-2009: A descriptive study. Am J Prev Med 2014; 46:150-7.
- Naleway AL, Gold R, Kurosky S, Riedlinger K, Henninger ML, Nordin JD, Kharbanda EO, Irving S, Cheetham TC, McCarthy NL. Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink. Vaccine 2013; 31:2898-903. Epub 2013 Apr 29.
- Naleway AL, Gold R, Drew L, Riedlinger K, Henninger ML, Gee J. Reported adverse events in young women following quadrivalent human papillomavirus vaccination. J Womens Health 2012; 21:425-35. Epub 2012 Jan 9.
- Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley MF, Klein NP, Weintraub E. Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink. Vaccine 2011; 29:8279-84. Epub 2011 Sep 9.
- Naleway AL, Smith WJ, Mullooly JP. Delivering influenza vaccine to pregnant women. Epidemiol Rev 2006; 28:47-53. Epub 2006 May 26.